8-KOther EventsExhibits & Filings

Cencora, Inc. 8-K Report, Corporate Update (Nov 2, 2011)

Filed November 2, 2011For Securities:COR

Summary

This 8-K filing from Cencora, Inc. (formerly AmerisourceBergen Corporation) on November 1, 2011, details two significant corporate actions impacting its financial flexibility and strategic positioning. Firstly, the company established a commercial paper program allowing for the issuance of up to $700 million in short-term unsecured promissory notes, fully supported by its existing revolving credit facility. This move enhances Cencora's ability to manage its short-term liquidity needs and optimize its capital structure. Secondly, and of greater strategic importance, Cencora announced the successful completion of its acquisition of TheraCom, LLC from CVS Caremark Corporation for $250 million, subject to working capital adjustments. TheraCom specializes in providing comprehensive support services to pharmaceutical and biotechnology manufacturers, including crucial reimbursement and patient assistance programs. This acquisition is expected to bolster Cencora's existing AmerisourceBergen Consulting Services business unit, likely expanding its service offerings and market reach within the life sciences sector.

Key Highlights

  • 1Cencora (AmerisourceBergen) established a $700 million commercial paper program to enhance short-term liquidity.
  • 2The commercial paper program is fully backed by a $700 million multi-currency revolving credit facility.
  • 3Completed the acquisition of TheraCom, LLC for $250 million (subject to customary working capital adjustments).
  • 4TheraCom, LLC provides support services to pharmaceutical and biotechnology drug manufacturers.
  • 5TheraCom's services include reimbursement and patient support programs.
  • 6The acquired TheraCom business will be integrated into AmerisourceBergen Consulting Services.
  • 7The acquisition signifies a strategic expansion into critical support services for drug manufacturers.

Frequently Asked Questions

The commercial paper program allows Cencora to issue up to $700 million in short-term unsecured promissory notes. This is a common treasury management tool that provides flexibility in managing short-term funding needs and optimizing cash flow.

The acquisition of TheraCom, LLC, for $250 million, strengthens Cencora's capabilities in supporting pharmaceutical and biotechnology drug manufacturers. TheraCom's expertise in reimbursement and patient support programs complements Cencora's existing consulting services, potentially expanding its revenue streams and market share in the life sciences value chain.

The purchase price for TheraCom was $250 million, subject to customary working capital adjustments. Investors should refer to future financial reports for detailed impacts on Cencora's balance sheet, income statement, and cash flows, including any goodwill recognized from the acquisition.

TheraCom, LLC is a subsidiary of CVS Caremark Corporation that specializes in providing a wide range of support services to pharmaceutical and biotechnology drug manufacturers. These services include critical functions such as reimbursement support and patient assistance programs, which are vital for the successful commercialization of new drugs.